Courtesy of Benzinga.com ETF Professor/SeekingAlpha
Van Eck’s Market Vectors unit, the fifth-largest U.S. ETF issuer by assets under management, has filed plans with the Securities and Exchange Commission to possibly introduce the Market Vectors Israel ETF.
The prospectus filed with the SEC includes ticker and expense ratio information, indicating Market Vectors could be close to bringing the fund to market. The Market Vectors Israel ETF will trade on the New York Stock Exchange under the ticker “ISRA” and have an annual expense ratio of 0.59 percent, according to the filing.
ISRA will compete directly with the iShares MSCI Israel Capped Investable Market Index Fund (EIS), which recently turned five years old.
ISRA will track the BlueStar Israel Global Index, which is a rules based, modified capitalization, free-float adjusted weighted index intended to give investors a means of tracking the overall performance of publicly traded companies that are generally considered to be Israeli companies, according to the filing.
There will be at least one major difference between the new Market Vectors Israel ETF and EIS: Weightings. Teva Pharmaceuticals (TEVA) accounts for 22.2 percent of the total weight in EIS, but no stock accounts for more than 12.5 percent of ISRA’s index.
For the full story at SeekingAlpha, please click here